Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for nasal polyp sufferers: Long-Term drug safety trial launches

NCT ID NCT06914908

ENROLLING_BY_INVITATION Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This study looks at the long-term safety and effectiveness of a drug called lunsekimig in adults with chronic sinusitis and nasal polyps that are not well controlled. Participants must have completed a previous lunsekimig study. The trial lasts about 56 weeks and measures side effects and symptom changes using questionnaires.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Alamo ENT Associates- Site Number : 8400001

    San Antonio, Texas, 78258, United States

  • ENT Associates of Texas - McKinne- Site Number : 8400014

    McKinney, Texas, 75070, United States

  • Eastern Virginia Medical School (EVMS) Medical Group- Site Number : 8400008

    Norfolk, Virginia, 23510, United States

  • Essential Medical Research- Site Number : 8400020

    Tulsa, Oklahoma, 74137, United States

  • Investigational Site Number : 0320001

    Buenos Aires, 1121, Argentina

  • Investigational Site Number : 0320002

    Rosario, Santa Fe Province, 2000, Argentina

  • Investigational Site Number : 0320003

    Mendoza, 5500, Argentina

  • Investigational Site Number : 0560001

    Leuven, 3000, Belgium

  • Investigational Site Number : 0560002

    Ghent, 9000, Belgium

  • Investigational Site Number : 1000001

    Sofia, 1612, Bulgaria

  • Investigational Site Number : 6160001

    Warsaw, Masovian Voivodeship, 00-909, Poland

  • Investigational Site Number : 6160002

    Krakow, Lesser Poland Voivodeship, 30-033, Poland

  • Investigational Site Number : 6160003

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Investigational Site Number : 6160004

    Poznan, Greater Poland Voivodeship, 60-693, Poland

  • Investigational Site Number : 6160005

    Warsaw, Masovian Voivodeship, 02-507, Poland

  • Investigational Site Number : 6160007

    Wroclaw, Lower Silesian Voivodeship, 50-750, Poland

  • Investigational Site Number : 8260001

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Investigational Site Number : 8260003

    Manchester, M13 9wl, United Kingdom

  • Investigational Site Number : 8260004

    Gloucester, Gloucestershire, GL1 3NN, United Kingdom

  • McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017

    Bellaire, Texas, 77401, United States

  • Modena Allergy + Asthma- Site Number : 8400005

    La Jolla, California, 92037, United States

  • Pharmaceutical Research & Consulting- Site Number : 8400004

    Dallas, Texas, 75231, United States

  • Sacramento Ear Nose & Throat - Roseville- Site Number : 8400003

    Roseville, California, 95661, United States

  • Treasure Valley Medical Research- Site Number : 8400002

    Boise, Idaho, 83706, United States

Conditions

Explore the condition pages connected to this study.